Medi-Cal youth gender-affirming services (APL 26-018): federal reimbursement limit from October 13, 2026 and hormone transition through April 12, 2027
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · High priority
DHCS All Plan Letter (APL) 26-018, Federal Reimbursement Limitation on Gender-Affirming Care Services for Youth, is listed in the DHCS letter index with the date 09/30/2026. As the October 11 article reported it, the letter limits reimbursement from October 13 for specified gender-affirming surgery, puberty blockers and hormone therapy for Medi-Cal members under 18 and Children's Health Insurance Program (CHIP) members under 19 (services for other medical indications and treatment of complications remain covered when medically necessary), keeps a transition through April 12, 2027 for hormones already being taken as of October 13 (for affected plan members, only under the medical benefit), and requires plans to submit policies, an attestation and copies within 90 calendar days of release, which the article gave as December 29.
Current status
The DHCS letter index, read in a browser on the evening of November 9, 2026 (Pacific time), still lists APL 26-018 with the date 09/30/2026 and an errata attachment. The letter itself was not read for this edition, so the letter details above are the October 11 article's and were not re-verified against the letter; verify them before relying on them. A member page from the Department of Health Care Access and Information (HCAI), published November 5, 2026, says that on October 13, 2026 the federal government stopped paying for some gender affirming care for youth, and that youth already taking gender affirming hormones as of October 13, 2026 can keep getting them through Medi-Cal until April 12, 2027. That page is an official source for those two dates. It does not state the plan submission date.
Who this affects
Medi-Cal managed care plans and their network hospitals and providers serving Medi-Cal members under 18 and CHIP members under 19.
Why it matters
As the October 11 article reported it: plans owe DHCS a submission and owe members notices, and providers face reimbursement limits for the listed services for the affected age groups. Verify the letter, its errata, any later DHCS guidance and any court action before acting on a date in this entry.
Required actions, as the earlier article reported them; not re-verified
- Medi-Cal managed care plans: submit policies, attestation and copies within 90 calendar days of the September 30 release (2026-12-29).
- Plans: distribute approved handbook errata and issue individualized adverse-action notices where required, with ten-day advance notice where applicable, appeal rights and continuation information.
- Plans (medical benefit): continue hormones already being taken as of October 13 through April 12, 2027.
Recommended action
- Apply service-date controls and exceptions in billing (Revenue Cycle, by 2026-11-20).
- Do not cancel or redirect care while state-only funding details develop; the October 11 article reported that the APL advises this, and it was not re-verified against the letter.
Implementation playbook
- Open APL 26-018, its errata and any later DHCS letter, check for litigation affecting it, and confirm the reimbursement limitation, the transition end date and the plan submission date. Owner: Managed Care and Compliance. Due: 2026-11-17.
- If the dates stand as the earlier article reported them, complete the plan policies, attestation and copies for submission. Owner: Managed Care. Due: the date confirmed in step 1 (the earlier article gave 2026-12-29).
- Confirm continuity arrangements for members already on hormone therapy. Owner: Medical Management. Due: the date confirmed in step 1 (the earlier article gave 2027-04-12).
Scope and timing
- Authority status
- Guidance, as the earlier article reported it; current status not verified
- Responsible owner
- Managed Care (affected: Clinical Operations, Case Management, Revenue Cycle, Legal)
- Other dates
- 2026-12-29: plan policies, attestation and copies due, as the October 11 article reported and not re-verified against the letter; 2027-04-12: youth already taking gender affirming hormones as of 2026-10-13 can keep getting them through Medi-Cal until this date, per HCAI's member page of November 5, 2026 (the October 11 article gave the same date); APL 26-018 released 2026-09-30 as the October 11 article reported; federal payment stopped for some gender affirming care for youth 2026-10-13, per HCAI's member page
Not established
APL 26-018 and its errata were not reopened; for the letter, only the DHCS index entry was read, so the letter's scope and its December 29 plan submission date are as the October 11 article reported them. The October 13, 2026 and April 12, 2027 dates are also stated on the HCAI member page, which was read. The related federal rule is tracked in a separate entry.
Earlier article: October 11, 2026 edition →
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →